01:04 , Dec 8, 2017 |  BC Innovations  |  Translation in Brief

ADAM and Ephrin

An October study in Nature Medicine from researchers at Harvard Medical School and the University of Montreal has shown inhibiting the cell surface protease ADAM10 could treat a form of idiopathic pulmonary fibrosis mediated by...
07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ephrin B2 (EFNB2); zinc finger E-box binding homeobox 2 (ZEB2)

Cancer INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting ZEB2 , a negative regulator of EFNB2 , could help treat glioblastoma multiforme (GBM). In samples from GBM patients, levels of EFNB2 were lower...
07:00 , Jul 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ephrin B2 (EFNB2)

Cancer INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest inhibiting EFNB2 could help treat glioblastoma multiforme (GBM). In patients, high tumor levels of EFNB2 correlated with poor survival. In a human GBM...
07:00 , Aug 13, 2015 |  BC Innovations  |  Tools & Techniques

Helping Beethoven hear

Little progress has been made in developing therapies for hearing loss that go beyond the temporary and partial solutions provided by hearing aids and cochlear implants, and most company activity is focused on acquired forms...
07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ephrin B2 (EFNB2)

Other INDICATION: Hearing loss Mouse studies suggest inhibition of EFNB2 could help treat hearing loss by converting cochlear support cells into hair cells in the ear. In newborn mice, EFNB2 knockout from cochlear support cells...
07:00 , May 20, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Ephrin B2 (EFNB2) In vitro and mouse studies suggest that inhibiting EFFB2 could be antiangiogenic and could help treat cancer. As compared with wild-type...
07:00 , Oct 23, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Kaposi's sarcoma Ephrin-B2 (EFNB2); EPH receptor B4 (EPHB4) Studies in mice suggest that inhibiting EFNB2 activity may be useful for treating...
07:00 , Apr 30, 2007 |  BioCentury  |  Strategy

MedImmune chronicles

MedImmune chronicles Since late 2000, MedImmune's stock performance has lagged its peers, as gauged by a price-weighted index consisting of Amgen (AMGN), Biogen Idec (BIIB), Genentech (DNA), Genzyme (GENZ) and Gilead (GILD). In fact, prior...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Company News

MedImmune Inc., VasGene deal

MEDI and VasGene partnered to develop VasGene's preclinical MAbs targeting Eph receptor B4 (EphB4) and its ligand, Ephrin B2 (Efnb2) , to treat cancer. MEDI is responsible for clinical development and commercialization of resulting products....
01:47 , Sep 9, 2005 |  BC Extra  |  Company News

MedImmune, VasGene antibody deal

MEDI and VasGene (Los Angeles, Calif.) partnered to develop VasGene's preclinical MAbs targeting Eph receptor B4 (EphB4) and its ligand, Ephrin B2 (Efnb2) , to treat cancer. MEDI is responsible for clinical development and commercialization...